Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the ...
Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast ...
Dizal Pharmaceutical will present new research findings on two of its innovative drugs - sunvozertinib and golidacitinib - at ...
Clinical Trials Arena on MSN10d
Pfizer and Arvinas’s HER2-breast cancer drug extends PFS in certain patientsPharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, ...
B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target.
Servier announces a strategic worldwide licensing agreement for Black Diamond Therapeutics' BDTX-4933 for solid tumors for an ...
Johnson & Johnson announced that new data from its oncology pipeline will be presented at the 2025 European Lung Cancer Congress, including ...
Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback